Prevalence and risk factors of osteoporosis in lupus nephritis patients in China: a cross-sectional study

BMC Nephrology

Table 3 Spearman rank correlation of BMD with demographics and clinical characteristics

Parameters	lumbar spine			total hip			femoral neck
Parameters	All	Premenopausal	Postmenopausal	All	Premenopausal	Postmenopausal	All	Premenopausal	Postmenopausal
Age	-0.180*	0.065	-0.041	-0.273**	-0.187	-0.077	-0.263**	-0.199	-0.075
Disease duration	0.054	-0.160	0.093	0.016	-0.278*	0.129	0.040	-0.194	0.115
Age at diagnosis of LN	-0.146	0.124	-0.059	-0.198*	-0.103	-0.108	-0.219*	-0.149	-0.121
Age at menopause	0.268*	-	0.268*	0.274*	-	0.274*	0.201	-	0.201
Menopause duration	-0.257*	-	0.257*	-0.275*	-	-0.275*	-0.257*	-	-0.257*
SLEDAI score	-0.138	-0.019	-0.197	-0.024	0.157	-0.181	-0.070	0.025	-0.140
Weight	0.311***	0.217	0.488***	0.387***	0.296*	0.552***	0.403***	0.220	0.626***
Height	0.408***	0.354**	0.367**	0.425***	0.333**	0.420***	0.422***	0.308*	0.458***
Body mass index	0.131	0.023	0.429***	0.211*	0.102	0.473***	0.237**	0.043	0.548***
Serum creatinine	0.183*	0.197	0.322**	-0.037	-0.104	0.070	-0.035	-0.121	0.112
Blood urea nitrogen	-0.039	0.044	0.050	-0.153	-0.029	-0.133	-0.131	0.034	-0.149
Uric acid	0.069	0.092	0.115	0.009	0.042	-0.014	0.052	-0.009	0.100
Serum correction calcium	0.003	0.134	-0.064	-0.075	-0.06	-0.082	-0.117	-0.082	-0.112
Duration of use glucocorticoids	0.016	-0.171	0.096	0.011	-0.203	0.143	-0.019	-0.218*	0.126
Current dosage of glucocorticoids	-0.002	0.180	-0.222	0.080	0.373**	-0.238	0.007	0.278*	-0.246*
Max dosage of glucocorticoids	-0.058	-0.080	-0.024	0.044	0.122	0.015	0.115	0.180	0.098

BMD, bone mineral density; LN, lupus nephritis; 95% CI, 95% confidence interval; SLEDAI Systemic Lupus Erythematosus Disease Activity Index
^*P < 0.05, ^**P < 0.01, ^***P < 0.001

ISSN: 1471-2369